{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:59:52Z","timestamp":1791500392582,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,2,11]],"date-time":"2010-02-11T00:00:00Z","timestamp":1265846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,2,11]],"date-time":"2010-02-11T00:00:00Z","timestamp":1265846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1038\/leu.2010.16","type":"journal-article","created":{"date-parts":[[2010,2,11]],"date-time":"2010-02-11T10:45:54Z","timestamp":1265885154000},"page":"765-770","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity"],"prefix":"10.1038","volume":"24","author":[{"given":"J R","family":"Engler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Frede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V A","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A C W","family":"Zannettino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T P","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D L","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,2,11]]},"reference":[{"key":"BFleu201016_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/300765a0","volume":"300","author":"A de Klein","year":"1982","unstructured":"de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982; 300: 765\u2013767.","journal-title":"Nature"},{"key":"BFleu201016_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/299747a0","volume":"299","author":"N Heisterkamp","year":"1982","unstructured":"Heisterkamp N, Groffen J, Stephenson JR, Spurr NK, Goodfellow PN, Solomon E et al. Chromosomal localization of human cellular homologues of two viral oncogenes. Nature 1982; 299: 747\u2013749.","journal-title":"Nature"},{"key":"BFleu201016_CR3","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.V83.8.2038.2038","volume":"83","author":"A Bedi","year":"1994","unstructured":"Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ . Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994; 83: 2038\u20132044.","journal-title":"Blood"},{"key":"BFleu201016_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.leu.2403241","volume":"18","author":"LS Steelman","year":"2004","unstructured":"Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA . JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004; 18: 189\u2013218.","journal-title":"Leukemia"},{"key":"BFleu201016_CR5","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408\u20132417.","journal-title":"N Engl J Med"},{"key":"BFleu201016_CR6","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","volume":"101","author":"R Bhatia","year":"2003","unstructured":"Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701\u20134707.","journal-title":"Blood"},{"key":"BFleu201016_CR7","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/sj.leu.2404893","volume":"22","author":"M Bocchia","year":"2008","unstructured":"Bocchia M, Ippoliti M, Gozzetti A, Abruzzese E, Calabrese S, Amabile M et al. CD34+\/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. Leukemia 2008; 22: 426\u2013428.","journal-title":"Leukemia"},{"key":"BFleu201016_CR8","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","volume":"104","author":"J Cortes","year":"2004","unstructured":"Cortes J, O\u2019Brien S, Kantarjian H . Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204\u20132205.","journal-title":"Blood"},{"issue":"Suppl 1","key":"BFleu201016_CR9","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.leukres.2003.10.017","volume":"28","author":"MJ Mauro","year":"2004","unstructured":"Mauro MJ, Druker BJ, Maziarz RT . Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 2004; 28 (Suppl 1): S71\u2013S73.","journal-title":"Leuk Res"},{"key":"BFleu201016_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58\u201360.","journal-title":"Blood"},{"key":"BFleu201016_CR11","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532\u20134539.","journal-title":"Blood"},{"key":"BFleu201016_CR12","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/sj.leu.2404609","volume":"21","author":"X Jiang","year":"2007","unstructured":"Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926\u2013935.","journal-title":"Leukemia"},{"key":"BFleu201016_CR13","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","volume":"108","author":"NE Jordanides","year":"2006","unstructured":"Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC . Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006; 108: 1370\u20131373.","journal-title":"Blood"},{"key":"BFleu201016_CR14","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","volume":"108","author":"DL White","year":"2006","unstructured":"White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006; 108: 697\u2013704.","journal-title":"Blood"},{"key":"BFleu201016_CR15","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"J Thomas","year":"2004","unstructured":"Thomas J, Wang L, Clark RE, Pirmohamed M . Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739\u20133745.","journal-title":"Blood"},{"key":"BFleu201016_CR16","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s00424-003-1089-9","volume":"447","author":"H Koepsell","year":"2004","unstructured":"Koepsell H, Endou H . The SLC22 drug transporter family. Pflugers Arch 2004; 447: 666\u2013676.","journal-title":"Pflugers Arch"},{"key":"BFleu201016_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s10254-003-0017-x","volume":"150","author":"H Koepsell","year":"2003","unstructured":"Koepsell H, Schmitt BM, Gorboulev V . Organic cation transporters. Rev Physiol Biochem Pharmacol 2003; 150: 36\u201390.","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"BFleu201016_CR18","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","volume":"110","author":"DL White","year":"2007","unstructured":"White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007; 110: 4064\u20134072.","journal-title":"Blood"},{"key":"BFleu201016_CR19","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1182\/blood-2005-02-0694","volume":"106","author":"LC Crossman","year":"2005","unstructured":"Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE . hOCT 1 and resistance to imatinib. Blood 2005; 106: 1133\u20131134; author reply 4.","journal-title":"Blood"},{"key":"BFleu201016_CR20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","volume":"83","author":"L Wang","year":"2008","unstructured":"Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE . Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008; 83: 258\u2013264.","journal-title":"Clin Pharmacol Ther"},{"key":"BFleu201016_CR21","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1182\/blood.V81.9.2215.2215","volume":"81","author":"RJ Arceci","year":"1993","unstructured":"Arceci RJ . Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993; 81: 2215\u20132222.","journal-title":"Blood"},{"key":"BFleu201016_CR22","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","volume":"104","author":"H Burger","year":"2004","unstructured":"Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump. Blood 2004; 104: 2940\u20132942.","journal-title":"Blood"},{"key":"BFleu201016_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/sj.leu.2403257","volume":"18","author":"T Illmer","year":"2004","unstructured":"Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschlagel U, von Bonin M et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004; 18: 401\u2013408.","journal-title":"Leukemia"},{"key":"BFleu201016_CR24","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1158\/0008-5472.CAN-03-3344","volume":"64","author":"PJ Houghton","year":"2004","unstructured":"Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004; 64: 2333\u20132337.","journal-title":"Cancer Res"},{"key":"BFleu201016_CR25","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1038\/sj.leu.2403853","volume":"19","author":"Y Zong","year":"2005","unstructured":"Zong Y, Zhou S, Sorrentino BP . Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia. Leukemia 2005; 19: 1590\u20131596.","journal-title":"Leukemia"},{"key":"BFleu201016_CR26","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/sj.leu.2404638","volume":"21","author":"C Brendel","year":"2007","unstructured":"Brendel C, Scharenberg C, Dohse M, Robey RW, Bates SE, Shukla S et al. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007; 21: 1267\u20131275.","journal-title":"Leukemia"},{"key":"BFleu201016_CR27","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.1016\/j.bmcl.2004.09.042","volume":"14","author":"PW Manley","year":"2004","unstructured":"Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Furet P, Mestan J et al. Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases. Bioorg Med Chem Lett 2004; 14: 5793\u20135797.","journal-title":"Bioorg Med Chem Lett"},{"key":"BFleu201016_CR28","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500\u20134505.","journal-title":"Cancer Res"},{"key":"BFleu201016_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129\u2013141.","journal-title":"Cancer Cell"},{"key":"BFleu201016_CR30","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.exphem.2009.02.006","volume":"37","author":"S Hatziieremia","year":"2009","unstructured":"Hatziieremia S, Jordanides NE, Holyoake TL, Mountford JC, Jorgensen HG . Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Exp Hematol 2009; 37: 692\u2013700.","journal-title":"Exp Hematol"},{"key":"BFleu201016_CR31","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","volume":"109","author":"HG Jorgensen","year":"2007","unstructured":"Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL . Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007; 109: 4016\u20134019.","journal-title":"Blood"},{"key":"BFleu201016_CR32","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319\u2013325.","journal-title":"Blood"},{"key":"BFleu201016_CR33","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/sj.leu.2405086","volume":"22","author":"H Konig","year":"2008","unstructured":"Konig H, Holtz M, Modi H, Manley P, Holyoake TL, Forman SJ et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 2008; 22: 748\u2013755.","journal-title":"Leukemia"},{"key":"BFleu201016_CR34","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00424-004-1355-5","volume":"449","author":"G Ciarimboli","year":"2005","unstructured":"Ciarimboli G, Schlatter E . Regulation of organic cation transport. Pflugers Arch 2005; 449: 423\u2013441.","journal-title":"Pflugers Arch"},{"key":"BFleu201016_CR35","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/jcp.20081","volume":"201","author":"G Ciarimboli","year":"2004","unstructured":"Ciarimboli G, Struwe K, Arndt P, Gorboulev V, Koepsell H, Schlatter E et al. Regulation of the human organic cation transporter hOCT1. J Cell Physiol 2004; 201: 420\u2013428.","journal-title":"J Cell Physiol"},{"key":"BFleu201016_CR36","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/00008571-200211000-00002","volume":"12","author":"R Kerb","year":"2002","unstructured":"Kerb R, Brinkmann U, Chatskaia N, Gorbunov D, Gorboulev V, Mornhinweg E et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 2002; 12: 591\u2013595.","journal-title":"Pharmacogenetics"},{"key":"BFleu201016_CR37","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.bbrc.2003.11.175","volume":"313","author":"T Sakata","year":"2004","unstructured":"Sakata T, Anzai N, Shin HJ, Noshiro R, Hirata T, Yokoyama H et al. Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem Biophys Res Commun 2004; 313: 789\u2013793.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFleu201016_CR38","doi-asserted-by":"publisher","first-page":"5902","DOI":"10.1073\/pnas.0730858100","volume":"100","author":"Y Shu","year":"2003","unstructured":"Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA 2003; 100: 5902\u20135907.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu201016_CR39","doi-asserted-by":"publisher","first-page":"747","DOI":"10.4161\/cbt.4.7.1826","volume":"4","author":"H Burger","year":"2005","unstructured":"Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G et al. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 2005; 4: 747\u2013752.","journal-title":"Cancer Biol Ther"},{"key":"BFleu201016_CR40","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1038\/leu.2009.166","volume":"23","author":"A Davies","year":"2009","unstructured":"Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, Harris RJ et al. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 2009; 23: 1999\u20132006.","journal-title":"Leukemia"},{"key":"BFleu201016_CR41","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","volume":"103","author":"S Chu","year":"2004","unstructured":"Chu S, Holtz M, Gupta M, Bhatia R . BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 2004; 103: 3167\u20133174.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201016","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T13:43:00Z","timestamp":1648734180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,11]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["BFleu201016"],"URL":"https:\/\/doi.org\/10.1038\/leu.2010.16","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,11]]},"assertion":[{"value":"1 September 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2009","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2009","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TP Hughes and DL White receive Honoraria and Grant Funding from Novartis Pharmaceuticals, and are members of Advisory Boards for Novartis. ACW Zannettino receives Grant Funding from Novartis Pharmaceuticals. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}